Clinical Trials Logo

Clinical Trial Summary

This study will examine the role of the brain chemical dopamine in people's response to alcohol consumption. Dopamine is thought to influence whether people have a strong or weak response to alcohol and how pleasurable that response is. The findings of this study may shed light on why some people are at higher risk of developing problem drinking behaviors.

Healthy normal volunteers between 21 and 25 years of age who have never had a serious problem with alcohol abuse or drug abuse may be eligible for this study. Candidates will be screened with a medical history and physical examination, and will be interviewed about their smoking and drinking behaviors. Participants will undergo test procedures on two separate days, as follows:

Test Day 1

Upon arrival at the Clinical Center, participants will take a breathalyzer test for alcohol and provide a urine sample for a drug screen. Women will also have a urine pregnancy test. They will then lie on a hospital bed and two intravenous catheters (IV lines) will be placed, one into each arm. One line will be used to collect blood samples during the test session; the other will be used to infuse alcohol into the bloodstream. The alcohol will rapidly increase the blood alcohol level to between 0.06 and 0.08 grams per deciliter. (0.08 g/dL is the level at which a person is charge with driving under the influence of alcohol in all States.) Before, during, and after the infusion, subjects will be asked about their feelings in response to the alcohol, such as confusion, elation, level of discomfort or dizziness, ability to concentrate, and so forth. At 35 and 60 minutes after the infusion begins, subjects will take a body sway test. This involves standing on a machine to determine how the alcohol has affected the sense of balance. Subjects will then relax in the clinic for a few hours. During this time, a blood sample will be collected and a questionnaire will be given hourly until the blood alcohol level has gone down to 0.02 g/dL. When the alcohol level has declined to 0.02 g/dL (usually 3 to 4 hours after the infusion), the subject will be sent home in a taxi.

Test Day 2

Participants will again take a breathalyzer test for alcohol and provide a urine sample for drug screen and, for women, a pregnancy test. Subjects will lie on a hospital bed and three IV lines will be inserted, one to draw blood samples, one to infuse alcohol, and one to give raclopride, a radioactive substance used for positron emission tomography (PET) scanning. For PET, the subject lies on a table in the scanner with a mask placed over his or her head to help hold the head still during the scan. After a brief scan to adjust the machine, a small amount of radioactive water (O-15 water) is injected through the IV line and a series of pictures is taken over a period of about 1 minute. These images show how the radioactive water distributes in the brain, indicating blood flow. After the water scan, raclopride is given through the IV line and more pictures of the brain are taken over the next 2 hours. Blood samples are collected during and after the raclopride scan. During this procedure, subjects are asked the same questions about their feelings in response to the alcohol as they did during the earlier session. After he scans, they will be monitored in the clinic with hourly blood tests and questionnaires until the blood alcohol concentration decreases to 0.02 g/dL and will then be sent home in a taxi.


Clinical Trial Description

Some persons are more likely to develop alcoholism than others. Understanding the difference between persons at high vs. low risk of developing alcoholism could be important for both prevention and treatment strategies.

Tolerance for the sedative effects of alcohol has been shown in young adults to predict development of alcoholism later in life. The basis for this increased risk is unclear. It may be that persons who tolerate alcohol well as young adults experience more of the rewarding effects of alcohol (e.g., euphoria), or that they experience less of the negative effects of alcohol (e.g., sedation), or some combination of the two. Fortunately, brain-imaging tools can shed light on the brain's reward response mechanisms to alcohol. Differences in the reward circuits of persons who experience a euphoric response to alcohol may help explain why some people go on to develop alcoholism while others do not. Both human and animal research point toward a difference in the density of dopamine receptors in the striatum of alcohol-preferring and non alcohol-preferring subjects. The following experiment is designed to examine the relationship between response to alcohol, dopamine receptor density in the striatum, and dopamine release in response to alcohol.

We propose classification of subjects as 'low response' or 'high response' on the basis of their level of response to a controlled alcohol challenge in the laboratory, using the established methods of Schuckit et al to gather systematic data on subjects' response to alcohol. Next, baseline levels of dopamine D2 receptor density in mesolimbic reward circuits of subjects in each group would be assessed in the PET scanner by using the radioactive dopamine antagonist C-11 raclopride. C-11 raclopride binds to D2 receptors, which will provide a signal proportional to the number of D2 receptors present. This will allow us to measure and compare the baseline D2 receptor density in high and low response groups. Directly after obtaining this baseline D2 receptor measurement, we propose administration of a controlled alcohol challenge. Acute alcohol administration causes release of dopamine in the striatum, and can dislodge a portion of the C-11 raclopride that was bound to D2 receptors. This will allow us to compare high and low response groups for differences in the displacement of C-11 raclopride induced by dopamine release, thereby providing a measure of dopamine release in response to alcohol.

The data obtained will allow us to compare the response to alcohol of young adults who are high vs. low responders. It will also permit comparison of these groups in terms of baseline striatal dopamine receptor density and striatal dopamine release in response to alcohol.

Results of this experiment may identify a physiological basis for the increased risk in some young adults for development of alcoholism. It may also provide a model for further studies of the relationship between response to alcohol, risk for developing alcoholism, and brain reward mechanisms. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00050219
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date November 2002
Completion date September 2004

See also
  Status Clinical Trial Phase
Completed NCT05037630 - Feasibility Evaluation of a Self-guided Digital Tool for Problematic Alcohol Use N/A
Completed NCT03037749 - Over-arousal as a Mechanism Between Alcohol and Intimate Partner Violence N/A
Enrolling by invitation NCT02927132 - Guilt and Expressive Writing for Reducing Alcohol Use in College Students N/A
Completed NCT02905123 - Brief Internet Intervention for Hazardous Alcohol Use N/A
Enrolling by invitation NCT02952495 - Online Education to Inform the Elderly About Age-related Alcohol Risks Phase 2
Completed NCT01923246 - Development of IVR and WEB Alcohol Interventions N/A
Completed NCT01129804 - Network Support for Alcohol Treatment 2 N/A
Completed NCT00374153 - Southern Methodist Alcohol Research Trial (SMART) N/A
Completed NCT01126164 - Parent Intervention to Reduce Binge Drinking N/A
Completed NCT00383838 - Self-Selected Brief Alcohol Intervention for Adolescents N/A
Completed NCT03408743 - Engineering an Online STI Prevention Program: CSE2 N/A
Recruiting NCT04957628 - AlcoTail - Implementation of Tailored Interventions
Recruiting NCT04164940 - Patient Trajectories for Older Adults Admitted to Hospital for Alcohol-related Problems
Completed NCT00292240 - Brief Youth Substance Use Intervention for Primary Care N/A
Completed NCT04804579 - Boston ARCH 4F Intervention to Reduce Fall Risk in People With HIV and Alcohol Use N/A
Completed NCT02387489 - A Clinical Trial of SBIRT Services in School-based Health Centers N/A
Completed NCT02188446 - Intensive Smoking and Alcohol Cessation Intervention in Bladder Cancer Surgery Patients N/A
Completed NCT01688245 - A Text Message Behavioral Intervention to Reduce Alcohol Consumption in Young Adults N/A
Withdrawn NCT01739842 - Kudzu Effects on Brain Ethanol Levels: Proton Spectroscopy Assessment Phase 2/Phase 3
Completed NCT00561587 - Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study Phase 2